Physician profile
Patrick Henke
NPI 1023638053
$707.38
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $326 · 2024: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $166.63 | 2023-2024 | Otezla, Prolia, Evenity |
| Dexcom, INC. | $106.07 | 2023 | Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.32 | 2024 | Jardiance |
| Lilly USA, LLC | $62.20 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $50.30 | 2024 | |
| Abbott Laboratories | $47.69 | 2024 | Proclaim |
| Novartis Pharmaceuticals Corporation | $46.96 | 2023 | |
| Novo Nordisk INC | $43.60 | 2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $36.66 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $24.56 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $18.95 | 2024 | Voquezna |
| Abbvie INC. | $16.36 | 2023 | |
| Viiv Healthcare Company | $16.08 | 2024 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Henke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.